Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Tatva Chintan Pharma Chem is scheduled to hold a virtual one-on-one meeting with ChrysCapital Associates LLP on August 06, 2026. The company will discuss publicly available information and no unpublished price sensitive information will be shared.
Jul 31 2026 18:03:31
Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Tatva Chintan Pharma Chem Limited will conduct a virtual one-to-one meeting with Ventura Securities Limited on July 30, 2026. The company confirmed no unpublished price-sensitive information will be shared during the interaction.
Jul 24 2026 13:04:24
Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Tatva Chintan Pharma will hold a virtual one-on-one investor meeting with Alchemy Capital Management Pvt. Ltd. on July 28, 2026. The discussions will be limited to publicly available information, ensuring no unpublished price sensitive information is shared.
Jul 22 2026 16:12:39
Tatva Chintan Pharma Chem Ltd - 543321 - Announcement Under Regulation 30-Company Update
Tatva Chintan Pharma conducted a groundbreaking ceremony on July 20, 2026, for its new greenfield manufacturing unit in Dahej, Gujarat. This expansion is part of the company's growth strategy to strengthen infrastructure and meet increasing market demands.
Jul 20 2026 18:49:37
Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Change in Directorate
Tatva Chintan Pharma has re-appointed its Managing Director, Mr. Chintan N. Shah, and two Whole-time Directors, Mr. Ajaykumar M. Patel and Mr. Shekhar R. Somani, for a three-year term. These re-appointments ensure leadership continuity for the company.
Jul 17 2026 15:52:09
Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 17.07.2026
Tatva Chintan Pharma Chem's Q1 FY27 cons. revenue increased 42.9% YoY to ₹1,670.55 million, with net profit up 140.3% YoY to ₹159.81 million. The board approved a ₹200 crore capacity expansion at its Dahej unit for 344 kilolitres of reactor capacity and increased borrowing limits to ₹1,000 crore, financed by internal accruals and debt, over the next 21 months.
Jul 17 2026 15:49:46
Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Friday, 17.07.2026
Tatva Chintan Pharma's board is scheduled to meet on July 17, 2026, to review and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.
Jul 10 2026 10:58:06
Read More